Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-26

Study Completion Date

2032-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cavernous sinus meningiomas are close to optic nerve, pituitary gland, cranial nerve, and hippocampi.

The doses delivered to these structures are crucial and radiotherapy of cavernous sinus meningiomas exposes patients to late secondary effects (pituitary deficit, nerve palsy, cognitive impairment…). In 2012, Gondi reported that a dose given to 40% of the bilateral hippocampi greater than 7.3 Gy is associated with long-term impairment in list-learning delayed recall after FSRT for benign or low-grade adult brain tumors.

There is no published or recruiting prospective study evaluating the impact of proton-therapy or conventional irradiation on neurocognitive function for meningioma patients. Notably, long-term cognitive or ocular impact of these modern irradiation schemes remains poorly known. Yet, these patients had a long life-expectancy, and are at risk of developing long-term sequelae. Thus, according to its ballistic advantage, an improvement of patient functional outcomes and a reduction of neurocognitive long-term toxicity are expected if tissue sparing proton-therapy is used.

In this context, a randomized prospective study, evaluating long-term toxicity of these two irradiation modalities (Proton Therapy (PRT) and photon radiotherapy (XRT)) seems crucial to further assess proton-therapy indication for these patients.

Although literature reports excellent outcomes for intracranial meningioma patients treated by proton-therapy, none of the eight retrospective studies found in the literature used an accurate and full evaluation of long-term toxicity

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:

NCT06036706

Meningioma Radiation Toxicity

RECRUITING NA

Cognition-preserving Brain Irradiation for Treating Patients With Intracranial Meningioma in the Era of Modern Radiotherapeutic Techniques Including Proton Beam Therapy - a Prospective Study Focusing on Radiological Outcomes and Neurocognitive Endpoints

NCT05832099

Intracranial Meningioma

NOT_YET_RECRUITING

Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy

NCT02913534

Brain Metastasis

COMPLETED

Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute

NCT02655744

Primary Central Nervous System Lymphoma

RECRUITING

Evaluation of Brain Functional Changes With 18F-FDG PET and Cognitive Processes After Brain Radiotherapy for Cavernous Sinus Meningiomas and Non-secreting ACTH Adenomas

NCT06180226

Meningioma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cavernous Sinus Meningioma Proton-therapy Photon Radiotherapy Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multicenter prospective comparative phase 3 randomized 1:1 trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

proton-therapy

Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)

Group Type EXPERIMENTAL

Proton-therapy

Intervention Type RADIATION

Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)

photon radiotherapy

Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)

Group Type ACTIVE_COMPARATOR

Photon radiotherapy

Intervention Type RADIATION

Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Proton-therapy

Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)

Intervention Type RADIATION

Photon radiotherapy

Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cavernous sinus meningioma for which clinical target volume is larger than 3 centimeters
* Anterior skull base meningioma, invading by contiguity the cavernous sinus can be included
* Histologic proven Grade I meningioma
* Meningioma for which biopsy is not safely achievable and for which growing and imaging criteria are in favour of grade I meningioma can be included
* Age \>18 years and ≤70 years
* Indication of irradiation validated by a pluridisciplinary meeting
* Adjuvant or exclusive irradiation is allowed.
* Use of conventional fractionation: 1.8Gy (RBE)/fraction
* Signed informed consent form
* WHO Performance status equal to 0 or 1
* Patient affiliated to the French social health insurance
* MoCA score ≥ cut-off of GRECOGVASC normative data (Roussel, 2016, cf annexe 1)
* Patient whose neuropsychological abilities allow to follow the requirements of the protocol

Exclusion Criteria

* Patient with mutation in a known predisposition gene (NF-2, SMARCE-1…)
* Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease and other dementias, organic psychosis (other than dementia), schizophrenia, and neurodegenerative disease
* Radiosurgery, hypofractionated regimen
* Other localization than cavernous sinus
* Histologic proven Grade II or III meningioma
* Patient with unadjusted antiepileptic drug
* Contraindication to MRI
* Patient with a history of brain irradiation
* Patient with a history of cancer in the last five years (excluding skin baso-cellular carcinoma)
* Pregnant/breastfeeding woman
* Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study
* Participation in a therapeutic trial for less than 30 days
* Patient deprived of freedom or under guardianship

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Francois Baclesse

Caen, , France

Site Status RECRUITING